Amarin calls on Banner, Catalent, Chemport and Equateq for AMR101 supply

- Last updated on GMT

Related tags: Pharmacology

Amarin has turned to CMOs to support the commercial launch of its prescription grade omega-3 fatty acid drug AMR101 for high triglyceride levels.

Under the contracts Catalent Pharma Solutions and Banner Pharmacaps Europe, the latter of which worked with Amarin on AMR101’s clinical development, will provide softgel encapsulation services.

In addition, UK based Equateq and South Korea’s Chemport will join an existing unnamed firm as suppliers of the drug’s active pharmaceutical ingredient (API).

Amarin CEO Joseph Zakrzewski said: "A primary 2011 goal for Amarin is to expand our global supply chain to support expected product demand, diversify our supply base and ensure cost-efficient supply.

“We believe that the addition of these suppliers position us, subject to regulatory approval, for an aggressive launch of AMR101​."

Related news

Show more

Related products

show more

Transforming Clinical Development

Transforming Clinical Development

PerkinElmer | 01-Jun-2021 | Technical / White Paper

The estimated cost of bringing a drug to market in the U.S. according to JAMA is $1 billion.1 The extreme cost of clinical trials urge biopharmaceutical,...

Q&A: Effective Drug Product Process Development

Q&A: Effective Drug Product Process Development

Catalent Pharma Solutions | 14-Jan-2021 | Insight Guide

In this Q&A, a Catalent Biologics expert shares his expertise with drug product process development challenges, risks and how to mitigate them, the...

Related suppliers

Follow us

Products

View more

Webinars